Sagimet Biosciences Inc.
SGMT
$2.21
$0.199.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.82% | -80.08% | -22.46% | 18.67% | -28.30% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43.47% | 4.87% | 67.28% | -55.34% | -28.56% |
| Change in Net Operating Assets | 160.97% | -506.64% | 916.02% | 35.36% | -147.70% |
| Cash from Operations | 43.67% | -247.34% | 9.25% | 12.35% | -82.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,478.53% | 100.83% | -2,605.23% | 115.29% | -- |
| Cash from Investing | 1,478.53% | 100.83% | -2,605.23% | 115.29% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 2,909.21% | -95.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 97.35% | 71.06% | -436.33% |
| Cash from Financing | -- | 100.00% | -100.03% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.80% | 76.56% | -179.52% | 480.62% | -132.04% |